 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Cyclooxygenase-2 Inhibitors and Heart Attacks: Varying Effects?
1 February 2005 | Volume 142 Issue 3 | Page I-21
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction." It is in the 1 February 2005 issue of Annals of Internal Medicine (volume 142, pages 157-164). The authors are S.E. Kimmel, J.A. Berlin, M. Reilly, J. Jaskowiak, L. Kishel, J. Chittams, and B.L. Strom.
What is the problem and what is known about it so far?
People commonly use nonsteroidal anti-inflammatory drugs (NSAIDs) to relieve pain. Examples of older NSAIDs include aspirin, ibuprofen (Advil or Motrin), and naproxen (Aleve). Although these older NSAIDs are fairly safe, they can irritate the lining of the stomach and can cause ulcers and bleeding. Cyclooxygenase-2 (COX-2) inhibitors are a new type of selective NSAIDs. Examples of COX-2 inhibitors are celecoxib (Celebrex), rofecoxib (Vioxx), and valdecoxib (Bextra). They inhibitors do not injure the stomach lining as much as older NSAIDs do and cause fewer stomach problems and ulcers. However, they also cost more and require a doctor's prescription. Also, some COX-2 inhibitors increase the risk for heart disease. For example, rofecoxib was withdrawn from the market in September 2004 because a large trial found that it increased the risk for heart attacks and strokes. We do not know whether other COX-2 inhibitors have similar or different risks.
Why did the researchers do this particular study?
To see whether the risk for having a heart attack was similar among people taking rofecoxib; celecoxib; and older, nonselective NSAIDs.
Who was studied?
1718 patients with a first, nonfatal heart attack and 6800 adults with no history of a heart attack. All patients were 40 to 75 years of age from 5 counties in Pennsylvania.
How was the study done?
The researchers identified patients with recent heart attacks who were discharged from 36 hospitals between May 1998 and December 2002. They also identified adults with no history of a heart attack who were living in the same geographic region. They interviewed all participants by telephone and asked them several questions about past NSAID use. Patients with heart attacks reported use during the week before to their heart attack, while others reported use during the week before the interview. The researchers then compared NSAID use between patients with heart attacks and those with no history of a heart attack.
What did the researchers find?
Older NSAIDs were associated with a decreased risk for heart attack. Almost one third of the adults with no history of a heart attack reported taking older NSAIDs, while only about one fifth of those with a heart attack reported using these drugs. About 2.5% of the adults in both groups reported that they took 1 of 2 COX-2 inhibitors that were examined in the study. Use of rofecoxib was associated with a 2.72-higher odds of heart attack than was use of celecoxib. Rofecoxib was also associated with a higher odds of heart attack compared with older NSAIDs. Whether celecoxib was associated with a similar odds of heart attack compared with older NSAIDs was not clear.
What were the limitations of the study?
Only about 50% of eligible adults completed interviews. The study was not a randomized trial. Drug use was self-reported.
What are the implications of the study?
The risk for heart disease with rofecoxib and celecoxib may differ.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  C. H. Hennekens and S. Borzak Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2008; 13(1): 41 - 50. [Abstract] [PDF]
|
|
|
|
 |
|
 G. P. Joshi, R. Gertler, and R. Fricker Cardiovascular Thromboembolic Adverse Effects Associated with Cyclooxygenase-2 Selective Inhibitors and Nonselective Antiinflammatory Drugs Anesth. Analg., December 1, 2007; 105(6): 1793 - 1804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P A Scott, G H Kingsley, C M Smith, E H Choy, and D L Scott Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials Ann Rheum Dis, October 1, 2007; 66(10): 1296 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C Waksman, A. Brody, and S. D Phillips Nonselective Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk: Are They Safe? Ann. Pharmacother., July 1, 2007; 41(7): 1163 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M E Farkouh, J D Greenberg, R V Jeger, K Ramanathan, F W A Verheugt, J H Chesebro, H Kirshner, J S Hochman, C L Lay, S Ruland, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib Ann Rheum Dis, June 1, 2007; 66(6): 764 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Oitate, T. Hirota, M. Takahashi, T. Murai, S.-i. Miura, A. Senoo, T. Hosokawa, T. Oonishi, and T. Ikeda Mechanism for Covalent Binding of Rofecoxib to Elastin of Rat Aorta J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1195 - 1203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J M Brophy, L E Levesque, and B Zhang The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction Heart, February 1, 2007; 93(2): 189 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. G. E. Zarraga and E. R. Schwarz Coxibs and Heart Disease: What We Have Learned and What Else We Need to Know J. Am. Coll. Cardiol., January 2, 2007; 49(1): 1 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Madhok, O. Wu, G. McKellar, and G. Singh Non-steroidal anti-inflammatory drugs--changes in prescribing may be warranted Rheumatology, December 1, 2006; 45(12): 1458 - 1460. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Schneider, L. E. Levesque, B. Zhang, T. Hutchinson, and J. M. Brophy Association of Selective and Conventional Nonsteroidal Antiinflammatory Drugs with Acute Renal Failure: A Population-based, Nested Case-Control Analysis Am. J. Epidemiol., November 1, 2006; 164(9): 881 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. McGettigan and D. Henry Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2 JAMA, October 4, 2006; 296(13): 1633 - 1644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chaiamnuay, J. J. Allison, and J. R. Curtis Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. Am. J. Health Syst. Pharm., October 1, 2006; 63(19): 1837 - 1851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Cheng Use of Non-Aspirin Nonsteroidal Antiinflammatory Drugs and the Risk of Cardiovascular Events Ann. Pharmacother., October 1, 2006; 40(10): 1785 - 1796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Oitate, T. Hirota, K. Koyama, S.-i. Inoue, K. Kawai, and T. Ikeda COVALENT BINDING OF RADIOACTIVITY FROM [14C]ROFECOXIB, BUT NOT [14C]CELECOXIB OR [14C]CS-706, TO THE ARTERIAL ELASTIN OF RATS Drug Metab. Dispos., August 1, 2006; 34(8): 1417 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Gislason, S. Jacobsen, J. N. Rasmussen, S. Rasmussen, P. Buch, J. Friberg, T. K. Schramm, S. Z. Abildstrom, L. Kober, M. Madsen, et al. Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction Circulation, June 27, 2006; 113(25): 2906 - 2913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hur, A. T Chan, A. C Tramontano, and G S. Gazelle Coxibs Versus Combination NSAID and PPI Therapy for Chronic Pain: An Exploration of the Risks, Benefits, and Costs Ann. Pharmacother., June 1, 2006; 40(6): 1052 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Andersohn, S. Suissa, and E. Garbe Use of First- and Second-Generation Cyclooxygenase-2-Selective Nonsteroidal Antiinflammatory Drugs and Risk of Acute Myocardial Infarction Circulation, April 25, 2006; 113(16): 1950 - 1957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. E Vonkeman, J. R B J Brouwers, and M. A F J van de Laar Understanding the NSAID related risk of vascular events. BMJ, April 15, 2006; 332(7546): 895 - 898. [Full Text] [PDF]
|
|
|
|
 |
|
 P.-A. Vendittoli, P. Makinen, P. Drolet, M. Lavigne, M. Fallaha, M.-C. Guertin, and F. Varin A Multimodal Analgesia Protocol for Total Knee Arthroplasty. A Randomized, Controlled Study J. Bone Joint Surg. Am., February 1, 2006; 88(2): 282 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Pijak, I. Huzicka, and F. Gazdik Coxibs and cardiovascular risk Can. Med. Assoc. J., October 11, 2005; 173(8): 852 - 852. [Full Text] [PDF]
|
|
|
|
|
|
D. Pratico and J.-M. Dogne Selective Cyclooxygenase-2 Inhibitors Development in Cardiovascular Medicine Circulation, August 16, 2005; 112(7): 1073 - 1079. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Antman, D. DeMets, and J. Loscalzo Cyclooxygenase Inhibition and Cardiovascular Risk Circulation, August 2, 2005; 112(5): 759 - 770. [Full Text] [PDF]
|
|
|
|
|
|
S C. Jones Relative Thromboembolic Risks Associated with COX-2 Inhibitors Ann. Pharmacother., July 1, 2005; 39(7): 1249 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Johnsen, H. Larsson, R. E. Tarone, J. K. McLaughlin, B. Norgard, S. Friis, and H. T. Sorensen Risk of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other NSAIDs: A Population-Based Case-Control Study Arch Intern Med, May 9, 2005; 165(9): 978 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D Martina, K. S Vesta, and T. L Ripley Etoricoxib: A Highly Selective COX-2 Inhibitor Ann. Pharmacother., May 1, 2005; 39(5): 854 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Is Risk for Nonfatal MI Greater with Vioxx Than with Celebrex? Journal Watch Cardiology, April 1, 2005; 2005(401): 5 - 5. [Full Text]
|
|
|
|
 |
|
 R. S. Bresalier, R. S. Sandler, H. Quan, J. A. Bolognese, B. Oxenius, K. Horgan, C. Lines, R. Riddell, D. Morton, A. Lanas, et al. Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial N. Engl. J. Med., March 17, 2005; 352(11): 1092 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 More Data on COX-2 Inhibitors Journal Watch (General), February 25, 2005; 2005(225): 2 - 2. [Full Text]
|
|
|
|
 |
|
 L. E. Levesque, J. M. Brophy, and B. Zhang The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults Ann Intern Med, February 8, 2005; (2005) 0000605-200504050-00113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Finckh and M. D. Aronson Cardiovascular Risks of Cyclooxygenase-2 Inhibitors: Where We Stand Now Ann Intern Med, February 1, 2005; 142(3): 212 - 214. [Full Text] [PDF]
|
|
|
|
|
|
L. E. Levesque, J. M. Brophy, and B. Zhang The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults Ann Intern Med, April 5, 2005; 142(7): 481 - 489. [Abstract] [Full Text] [PDF]
|
|
Read all Rapid Responses
| |||||||||||||||||||||||||||||||||||||||||||||||||
Article
